A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Bortezomib (Primary) ; Tanespimycin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 04 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 27 Dec 2007 The expected completion date for this trial is now 1 Jul 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top